Xin Lu

ORCID: 0000-0001-8054-6940
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Advanced Combustion Engine Technologies
  • Combustion and flame dynamics
  • Asthma and respiratory diseases
  • Combustion and Detonation Processes
  • Ovarian cancer diagnosis and treatment
  • Gestational Trophoblastic Disease Studies
  • Prenatal Screening and Diagnostics
  • PARP inhibition in cancer therapy
  • Allergic Rhinitis and Sensitization
  • Endometrial and Cervical Cancer Treatments
  • Pediatric health and respiratory diseases
  • Sinusitis and nasal conditions
  • Childhood Cancer Survivors' Quality of Life
  • X-ray Diffraction in Crystallography
  • Crystallization and Solubility Studies
  • Toxin Mechanisms and Immunotoxins
  • Genomic variations and chromosomal abnormalities
  • Respiratory Support and Mechanisms
  • Endometriosis Research and Treatment
  • Gynecological conditions and treatments
  • Ectopic Pregnancy Diagnosis and Management
  • Ovarian function and disorders
  • Cancer Genomics and Diagnostics
  • Inflammasome and immune disorders

Sanofi (United States)
2019-2024

Medicines Evaluation Unit
2024

University of Ferrara
2024

German Center for Lung Research
2024

Manchester University NHS Foundation Trust
2024

LungenClinic Grosshansdorf
2024

Xi'an Jiaotong University
2016-2023

Obstetrics and Gynecology Hospital of Fudan University
2010-2023

University of Wisconsin–Madison
2020

Shanghai Huangpu District Central Hospital
2018

In some patients with chronic obstructive pulmonary disease (COPD), type 2 inflammation may increase exacerbation risk and be indicated by elevated blood eosinophil counts. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 interleukin-13, key drivers of inflammation.In phase 3, double-blind, randomized trial, we assigned COPD who had count at least 300 per microliter an despite use standard triple therapy to receive dupilumab (300 mg) or...

10.1056/nejmoa2303951 article EN New England Journal of Medicine 2023-05-21

This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients platinum-sensitive recurrent ovarian cancer.In this phase III, double-blind, placebo-controlled conducted at 30 centers China, adults cancer who had responded to their most recent platinum-containing chemotherapy were randomized 2 : 1 receive oral niraparib (300 mg/day) or matched placebo until disease progression unacceptable toxicity (NCT03705156). Following...

10.1016/j.annonc.2020.12.018 article EN cc-by-nc-nd Annals of Oncology 2021-01-14

Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, key central drivers of type 2 inflammation, has shown efficacy safety in phase 3 trial involving patients with chronic obstructive pulmonary disease (COPD) inflammation an elevated risk exacerbation. Whether findings would be confirmed second was unclear.

10.1056/nejmoa2401304 article EN New England Journal of Medicine 2024-05-20

Patients with asthma and/or chronic rhinosinusitis nasal polyps (CRSwNP) experience recurrent respiratory tract infections. Dupilumab targets type 2 inflammation, a common underlying pathophysiology of both conditions, proven efficacy.To examine investigator-reported infection adverse events and anti-infective medication use dupilumab versus placebo in patients moderate-to-severe or severe CRSwNP.We performed post hoc analysis the pivotal phase 3 trials LIBERTY ASTHMA QUEST (NCT02414854) NP...

10.1016/j.jaip.2021.12.006 article EN cc-by-nc-nd The Journal of Allergy and Clinical Immunology In Practice 2021-12-22

Abstract The association of pseudo-Meigs' syndrome, elevation CA 125 to the struma ovarii is a rare condition. So far only nine cases have been reported in English literature through MEDLINE search. Here we report 46-year-old case ovarii, presented with ascites, hydrothorax, right ovarian mass and elevated serum level. These findings were misdiagnosed for an malignancy at first impression. Immediate resolution hydrothorax normalization level followed by removal. Struma could be cause 125....

10.1186/1757-2215-3-18 article EN cc-by Journal of Ovarian Research 2010-07-29

Laminar flame speeds of ethyl tertiary butyl ether (ETBE) were measured in a constant volume bomb at different initial temperatures (298 K, 373 453 K) and pressures (1 atm, 3 5 atm). The laminar experiments also conducted for methyl (MTBE), ethanol, iso-octane, gasoline the comparison Markstein lengths. Experimental results show that peak equivalence ratio 1.1 all tested fuels. Ethanol has fastest speed other fuels have similar speeds, indicating replacing MTBE with ETBE will not influence...

10.1021/acs.energyfuels.7b03636 article EN Energy & Fuels 2018-02-06

SummaryMedical records of 32 women with abdominal incision endometriosis who underwent surgical treatment in the Obstetrics and Gynaecology Hospital at Fudan University between September 1999 March 2006 were reviewed retrospectively. All cases concerning diagnosis confirmed by two gynaecological pathologists. The median age was years (range from 25 to 45). A total 31 patients had a history caesarean section, one case ovarian endometrioid cystectomy. presented mass scar. Among them, there 30...

10.1080/01443610802463744 article EN Journal of Obstetrics and Gynaecology 2008-01-01

Uncertainties in measurement of the laminar flame speed and Markstein length result from various aspects, which methodology extrapolation is believed to be an important factor; present work focusing on reducing uncertainties associated with extrapolations. A new nonlinear method (NL4) proposed though further derivation original model, expressed series form. Along available linear model (L) three models (NL1, NL2, NL3), NL4 numerically analyzed results indicate that it most accurate for...

10.1080/00102202.2017.1305369 article EN Combustion Science and Technology 2017-03-15
Coming Soon ...